Multi-Cannabinoid Oral Blend for Semaglutide-Associated Nausea and Chronic Neuropathic Pain: A Case Report

Thomas Andersen
Managing Editor
[email protected]
April 22, 2026

Abstract

Background

Cannabinoid-based symptom management remains an area in which patient-reported therapeutic responses may exceed or differ from effects documented in controlled clinical research. Published evidence most strongly supports cannabinoid use for selected chronic pain states and chemotherapy-associated nausea.¹–⁶ In contrast, evidence for obesity-related inflammation, functional dyspepsia, and glucagon-like peptide-1 (GLP-1) receptor agonist-associated gastrointestinal symptoms remains limited or indirect.¹²,¹⁸,¹⁹

This case is notable because the patient reportedly experienced meaningful benefit from a defined oral multi-cannabinoid blend despite more than 20 years of cannabis use and the expected CB1 receptor downregulation/desensitization associated with long-term exposure.

Case Presentation

This case describes a 43-year-old adult male weighing approximately 290 lb, with morbid obesity, semaglutide-associated nausea, chronic injury-related pain, radiculopathy, neuropathic pain, and obesity-associated knee and back inflammatory discomfort. The patient had a greater than 20-year history of cannabis smoking and used a defined oral cannabinoid blend for targeted symptom management.

Intervention

The oral cannabinoid regimen consisted of both major and minor cannabinoids in a designed blend – THC, THCv, CBD, CBDa, CBG, and CBN – administered in fixed oral doses. Per dose, the regimen included 100 mg THC, 20 mg THCv, 25 mg CBD, 25 mg CBDa, 25 mg CBG, and 20 mg CBN, for a total cannabinoid exposure of 215 mg. THCv was intentionally included to reduce THC-associated hyperphagia and because of its potential metabolic relevance.²³–²⁶

Outcomes

Symptoms and outcomes are rated on a 1-10 scale, with 1 indicating no symptoms and 10 indicating severe symptoms. Following administration of the cannabinoid blend, the patient reported improvement in inflammation, bloating, and nausea, with onset at approximately 60 minutes, peak benefit at approximately 90 minutes, and duration of benefit of approximately 6 hours. Nausea severity reportedly decreased from 7/10 to 1–2/10, and pain severity from 5–7/10 to 1–3/10. Additional reported benefits included reduced appetite effects relative to expected THC-associated hunger, improved sleep, improved mobility, and better tolerance of semaglutide therapy.

Conclusion

The magnitude and quality of the reported response appeared greater than would be predicted from the limited current clinical literature. This case highlights the gap between conservative evidence-based expectations and potentially meaningful individualized outcomes in complex cannabinoid regimens. The result suggests that careful documentation of real-world cannabinoid use may help advance clinical understanding.

Introduction

Cannabinoid-based therapeutics continue to occupy a complex position in clinical medicine, with patient-reported responses sometimes appearing to exceed or differ from effects documented in controlled research settings. The published literature most strongly supports both major and minor cannabinoid use in selected chronic pain states and chemotherapy-associated nausea.¹–⁶ By contrast, evidence for cannabinoid-based therapies for obesity and GLP-1 agonist-associated gastrointestinal symptoms related to nausea, inflammatory discomfort, bloating, and functional dyspepsia remains limited, indirect, or mechanistically inferred.¹²,¹⁸,¹⁹

Long-term heavy cannabis exposure introduces an additional interpretive challenge. In such patients, CB1 receptor downregulation/desensitization and functional tolerance would be expected to reduce sensitivity to certain THC-mediated effects, including analgesic, antiemetic, appetite, and psychoactive responses. Against that background, the present case is clinically notable because the patient reportedly experienced substantial benefit from a defined oral multi-cannabinoid regimen despite prolonged cannabis exposure and the expected physiology of tolerance.

This report describes the symptom profile, cannabinoid formulation, observed response pattern, and mechanistic considerations associated with a defined oral blend consisting of THC, THCv, CBD, CBDa, CBG, and CBN in an adult male with semaglutide-associated nausea, chronic neuropathic and injury-related pain, and obesity-associated knee and back inflammatory discomfort.⁷–²⁵

Patient Information

The patient is a 43-year-old adult male, 5’9” tall, weighing approximately 290 lb as of the date of this publication, with a clinical context notable for morbid obesity and concurrent semaglutide therapy. He also has a greater than 20-year history of cannabis smoking.

The patient began a health and wellness journey approximately 6 months ago to regain control of and quality of his life, after an annual physical indicated multiple adverse biomarkers, including high cortisol, high blood sugar, and high triglycerides. The patient presented at 350lbs on October 1st, 2025. Since then, the patient has had a dedicated exercise regimen and a disciplined diet, while beginning and maintaining GLP-1 therapy. This peptide, which has its own set of side effects, was evaluated and found to be an appropriate medical adjunct to diet and exercise.

The symptoms targeted by the cannabinoid regimen included semaglutide-associated nausea, semaglutide-associated bloating and upper gastrointestinal discomfort, chronic pain related to prior injuries, radiculopathy and neuropathic pain, and knee and back pain/inflammatory discomfort associated with obesity.

Clinical Context and Rationale

This case should be interpreted in the context of long-term heavy cannabis use, which would be expected to produce some degree of CB1 receptor downregulation/desensitization and functional tolerance. That background might be expected to blunt certain THC-mediated effects, including analgesic, antiemetic, appetite, and psychoactive responses. Despite that, the patient reportedly experienced clinically significant therapeutic benefit following use of the defined oral regimen.

The formulation was designed around three principal therapeutic goals. First, THC was used as the primary therapeutic driver for pain and nausea.¹–⁶ Second, THCv was intentionally included to blunt THC-induced appetite stimulation.²³–²⁶ Third, CBD, CBDa, CBG, and CBN were included to support pain, inflammation, nausea, overall symptom modulation, and rest-related symptom burden.⁷–²²

The patient’s symptom pattern suggests three major therapeutic targets. The first was semaglutide-associated nausea occurring in the setting of GLP-1 agonist therapy. In this context, cannabinoids may have functioned as symptom suppressors rather than correcting the underlying mechanism.⁴–⁶,¹⁰–¹⁷ The second was chronic neuropathic and injury-related pain, including radiculopathy-related discomfort resulting in persistent injury-related pain.¹–³ The third was obesity-related knee and back inflammatory pain/discomfort, in which symptom relief may have reflected reduced pain perception and improved tolerance of chronic tissue stress more than reversal of the underlying mechanically driven inflammatory burden.⁷–⁹,¹⁸,¹⁹

Intervention

The patient used a defined oral multi-cannabinoid blend administered with meals as part of a 2-to-3-times-per-day regimen. Total cannabinoid exposure was 215 mg per dose. The regimen was designed as a defined oral blend rather than an ad hoc combination, with each component selected for a stated role within the overall symptom-management strategy. THC served as the primary therapeutic driver for pain and nausea. THCv was intentionally included to reduce THC-associated hyperphagia.²³–²⁶ CBD, CBDa, and CBG were intended to support pain, inflammation, nausea, bloating, and overall symptom modulation,⁷–¹⁹, while CBN was included to support calming, rest, and recovery.²⁰–²²

Observed Effects

Based on the documented observations, the patient’s response appeared more therapeutically meaningful than a conservative literature-based prediction would suggest. Reported effects included improvement in inflammation, bloating, and nausea; reduction in pain severity; reduced appetite effects relative to expected THC-associated hunger; improved sleep; improved mobility; and better tolerance of semaglutide therapy.

The most clinically notable benefits were control of nausea, pain reduction, reduced bloating, perceived improvement in inflammation, and enhanced functional tolerability. These effects were observed despite long-term heavy cannabis exposure and the expected presence of tolerance physiology.

Observed Patient Course

Following administration of the defined cannabinoid blend, the patient reported improvement in inflammation, bloating, and nausea, with onset at approximately 60 minutes, peak benefit at approximately 90 minutes post-dose, and a duration of benefit of approximately 6 hours.

Symptoms and outcomes are rated on a 1-10 scale, with 1 indicating no symptoms and 10 indicating severe symptoms. Nausea severity reportedly changed from 7/10 to 1–2/10. Pain severity reportedly changed from 5–7/10 to 1–3/10. Appetite effects were reduced, with THCv included specifically to blunt THC-associated hunger.²³–²⁶ Functional outcomes included improved sleep, improved mobility, and better tolerance of semaglutide therapy.

Outcomes

At present, the case supports the conclusion that the patient experienced a reproducible therapeutic response to the cannabinoid blend, with the greatest apparent benefit in nausea control, pain reduction, relief of neuropathic and radiculopathy symptoms, reduced bloating, improved functional tolerance, and possible moderation of THC-associated appetite stimulation.

The effect on obesity-related inflammation is best characterized by a reduction in inflammatory discomfort within the broader reported response pattern. The observed response was notable not only for symptom reduction but also for its apparent functional relevance, including improved sleep, mobility, and tolerance of semaglutide treatment.

Discussion

This case is notable because the observed benefit appears greater than would be predicted from current conservative clinical evidence, highlighting the value of sharing novel clinical experiences to advance understanding.

First, the regimen was a multi-cannabinoid oral blend rather than isolated THC or CBD. The combined use of THC, THCv, CBD, CBDa, CBG, and CBN may have produced a therapeutic profile not well represented in standard clinical trials.¹–³,⁷–²²

Second, the patient had long-term cannabis exposure, which may have altered receptor sensitivity and shifted the balance between desired and undesired effects. In some patients, tolerance may reduce unwanted psychoactive effects while preserving sufficient therapeutic activity to support function.

Third, the symptom cluster itself may be especially relevant. The combination of GLP-1-associated nausea, neuropathic pain, chronic musculoskeletal pain, and bloating may respond differently to cannabinoids than isolated pain or isolated nausea conditions typically studied in trials.¹–⁶,¹⁰–¹⁹

Fourth, the use of THCv specifically to counter appetite stimulation adds a purposeful design element to the regimen. Even if this strategy is not strongly proven in clinical trials, it is mechanistically plausible and may have contributed to improved tolerability.²³–²⁶

Overall, this case suggests that individualized cannabinoid formulations may sometimes produce clinically meaningful results that are underrepresented in the existing literature, especially when evaluated through the lens of functional improvement rather than single-symptom score reduction.

Limitations

This report remains observational and is limited by the absence of standardized formal outcome instruments, biomarker data, imaging correlation, and controlled comparison conditions. It also does not establish causation.

Additional strength would come from repeated-dose tracking, consistent pre- and post-dose numeric symptom ratings, logging of adverse effects, and documentation across multiple sessions. Even so, this case contributes a clinically interesting real-world observation involving a defined oral multi-cannabinoid regimen in a patient with overlapping gastrointestinal, neuropathic, and inflammatory symptom burdens.

Conclusion

This case describes an adult male with morbid obesity, semaglutide-associated nausea, chronic neuropathic and injury-related pain, and long-term heavy cannabis exposure who experienced notable therapeutic benefit from a defined oral multi-cannabinoid regimen.

The most prominent benefits included nausea reduction, pain relief, reduced bloating, reduced appetite effects, and enhanced functional tolerance, including improved sleep, mobility, and tolerance to semaglutide therapy. The magnitude and quality of the reported response appear greater than would be predicted by the limited clinical research available, highlighting the importance of careful real-world documentation in complex cannabinoid therapeutics.¹–²⁶

Declarations

Consent for Publication

The patient described in this report is the author of the manuscript and consents to publication of the clinical information contained herein.

Conflict of Interest

The author declares no conflicts of interest.

Funding

No external funding was received for the preparation of this manuscript.

Author Contribution

The author conceived the report, documented the case details, reviewed the relevant literature, and prepared the manuscript.

Table 1. Patient Profile and Symptom Targets

Variable	Details
Age	43 years
Sex	Male
Weight	Approximately 290 lb
Relevant comorbidity context	Morbid obesity, high blood sugar
Cannabis exposure history	Greater than 20 years of heavy cannabis smoking
Concurrent medication context	Semaglutide (GLP-1 receptor agonist)
Primary symptom targets	Semaglutide-associated nausea; bloating/upper GI discomfort; chronic injury-related pain; pinched nerve pain; neuropathic pain; knee and back inflammatory discomfort

Table 2. Oral Multi-Cannabinoid Regimen

Compound	Amt per unit	Formula	Qty taken	Total mgs consumed	Indication/rationale
THC	10 mg	Gummy	2	20 mg	Neuropathic pain; anti-emetic properties
THC	20 mg	Indica tablet	4	80 mg	Targeted pain relief with strain-specific terpenes formulated for relaxation and sedation
THCv	10 mg	Gummy	2	20 mg	Appetite suppressant; aids in maintaining low blood sugar
CBD	25 mg	Tablet	1	25 mg	Anti-emetic; anti-inflammatory; COX inhibitor
CBDa	25 mg	Tablet	1	25 mg	Strong antiemetic; COX inhibitor; anti-inflammatory
CBG	25 mg	Tablet	1	25 mg	GI inflammation; bloating; anti-inflammation
CBN	20 mg	Gummy	1	20 mg	Promotes rest and recovery

Table 3. Reported Clinical Response

Domain	Pre-dose status	Post-dose status	Response characteristics
Nausea	7/10	1–2/10	Onset approximately 60 min; peak approximately 90 min; duration approximately 6 h
Pain	5–7/10	1–3/10	Reduction in overall pain burden during the active effect window
Bloating	Symptomatic	Improved	Improvement reported during the active effect window
Inflammation	Symptomatic inflammatory discomfort	Improved	Perceived improvement in inflammatory discomfort
Appetite effects	Expected THC-associated hunger	Reduced relative hunger	THCv is included to blunt THC-associated appetite stimulation
Sleep	Impaired/rest burden present	Improved	Improved sleep reported
Mobility	Limited by pain/discomfort	Improved	Improved mobility reported
Semaglutide tolerability	Limited by nausea/GI symptoms	Improved	Better tolerance of semaglutide reported

References

1. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473.
   https://jamanetwork.com/journals/jama/fullarticle/2338251
2. Sainsbury B, Bloxham J, Pour MH, Padilla M, Enciso R. Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis. J Dent Anesth Pain Med. 2021;21(6):479-506.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC8637910/
3. Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20(6):E755-E796.
   https://pubmed.ncbi.nlm.nih.gov/28934780/
4. Tramèr MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323(7303):16-21.
   https://pubmed.ncbi.nlm.nih.gov/11440936/
5. May MB, Glode A. Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics. Cancer Manag Res. 2016;8:49-55.
   https://pubmed.ncbi.nlm.nih.gov/27274310/
6. Mersiades A, Goutzamanis S, Broomfield A, et al. Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a pilot randomized, placebo-controlled trial. Support Care Cancer. 2018;26(11):4123-4130.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC6144412/
7. Burstein S. Cannabidiol and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015;23(7):1377-1385.
   https://pubmed.ncbi.nlm.nih.gov/25703248/
8. Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel). 2020;9(1):21.
   https://pubmed.ncbi.nlm.nih.gov/31878089/
9. Cosentino M, Marino F, Bombelli R, et al. Effect of cannabidiol on cyclooxygenase type 1 and 2 expression and function in human neutrophils. Cannabis Cannabinoid Res. 2023;8(3):508-519.
   https://pubmed.ncbi.nlm.nih.gov/35930236/
10. Rock EM, Parker LA. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behavior via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol. 2012;165(8):2620-2634.
    https://pubmed.ncbi.nlm.nih.gov/21827451/
11. Parker LA, Rock EM, Limebeer CL. Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol. 2011;163(7):1411-1422.
    https://pubmed.ncbi.nlm.nih.gov/21175589/
12. Rock EM, Limebeer CL, Parker LA. Therapeutic potential of cannabidiol, cannabidiolic acid, and cannabidiolic acid methyl ester as treatments for nausea and vomiting. Cannabis Cannabinoid Res. 2022;7(4):444-455.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC8380783/
13. Takeda S, Misawa K, Yamamoto I, Watanabe K. Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis. Drug Metab Dispos. 2008;36(9):1917-1921.
    https://pubmed.ncbi.nlm.nih.gov/18556441/
14. Takeda S, Ikeda E, Su S, et al. Down-regulation of cyclooxygenase-2 by cannabidiolic acid in human breast cancer cells. J Toxicol Sci. 2014;39(5):711-716.
    https://pubmed.ncbi.nlm.nih.gov/25242400/
15. Bolognini D, Rock EM, Cluny NL, et al. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behavior in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol. 2013;168(6):1456-1470.
    https://pubmed.ncbi.nlm.nih.gov/23121618/
16. Rock EM, Limebeer CL, Petrie GN, Williams LA, Mechoulam R, Parker LA. Effect of cannabidiolic acid and ondansetron on experimentally induced nausea and vomiting in rats. Br J Pharmacol. 2013;169(3):685-692.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC3682714/
17. Borrelli F, Fasolino I, Romano B, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 2013;85(9):1306-1316.
    https://pubmed.ncbi.nlm.nih.gov/23415610/
18. Camilleri M. Cannabinoids and gastrointestinal motility: pharmacology, clinical effects, and potential therapeutics in humans. Neurogastroenterol Motil. 2018;30(9):e13370.
    https://pubmed.ncbi.nlm.nih.gov/29745439/
19. Crowley K, et al. Effects of cannabinoids on intestinal motility, barrier function, and inflammation. Biomolecules. 2024.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC11203611/
20. Lavender IG, et al. Cannabinol for acute treatment of insomnia disorder in a randomized, double-blind, placebo-controlled trial. J Sleep Res. 2026.
    https://pubmed.ncbi.nlm.nih.gov/41698831/
21. Lavender IG, Suraev A, Marshall NS, et al. Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day functioning in people with insomnia disorder: protocol for a randomized double-blind placebo-controlled trial. BMJ Open. 2023;13(8):e071148.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC10450062/
22. Arnold JC et al. A sleepy cannabis constituent: cannabinol and its active metabolite alter sleep architecture in rats. Neuropsychopharmacology. 2025.
    https://www.nature.com/articles/s41386-024-02018-7
23. Rzepa E, Tudge L, McCabe C. The CB1 neutral antagonist tetrahydrocannabivarin reduces resting-state functional connectivity and increases connectivity in the cognitive control network and dorsal visual stream network in overweight and obese subjects. Int J Neuropsychopharmacol. 2016;19(2):pyv112.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC4772823/
24. Tudge L, Williams C, Cowen PJ, McCabe C. Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. Int J Neuropsychopharmacol. 2015;18(6):pyu094.
    https://pubmed.ncbi.nlm.nih.gov/25542687/
25. Mendoza S, et al. The role of tetrahydrocannabivarin (THCv) in metabolic disorders: an updated review. Biomed Pharmacother. 2025.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC12011981/
26. Jadoon KA, Ratcliffe SH, Barrett DA, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016;39(10):1777-1786.
    https://pubmed.ncbi.nlm.nih.gov/27573936/